This dual-targeting strategy has been validated by a CD47/PD-L1 bispecific antibody (6MW3211), which demonstrated potent synergistic anti-tumor efficacy in preclinical models and a favorable safety profile in GLP non-human primate studies, underscoring its clinical translation potential [116]. This evidence concerns the gene CD47 and neoplasm.